The gastrin-releasing peptide receptor (GRPR) has been identified as a promising target for cancer imaging and therapy as it is overexpressed in various solid tumors, e.g., prostate, breast, and gastrointestinal stromal tumors (GIST). Here, GRPR is linked to cancer.